Literature DB >> 26639463

Incidence of Autoantibodies to C1Q Complement Component in Women with Miscarriages and Autoantibodies to Phospholipids and Chorionic Gonadotropin.

I V Menzhinskaya1, L V Van'ko2, M M Kashentseva2, P A Kiryushchenkov2, G T Sukhikh2.   

Abstract

Autoantibodies to C1q complement component are often detected in patients with autoimmune diseases. The complement system is involved in the pathophysiology of gestosis. The incidence of anti-C1q autoantibodies was studied in women with miscarriages and autoantibodies to phospholipids and chorionic gonadotropin. Serum C3 and C4 complement components and anti-C1Q autoantibodies (IgG) were measured by ELISA. The median levels of C3 and C4 in patients with miscarriages were lower than in healthy women. Anti-C1q autoantibodies were more often found in the patients than in controls; patients with autoantibodies to phospholipids formed a risk group. Median levels of anti-C1q autoantibodies were higher in the patients with autoantibodies to phospholipids and chorionic gonadotropin than in healthy women. Hence, activation of the complement system and hyperproduction of anti-C1q autoantibodies were unfolding in patients with miscarriages, mainly in the patients with autoantibodies to phospholipids.

Entities:  

Keywords:  antiphospholipid autoantibodies; autoantibodies to chorionic gonadotropin; autoantibodies to complement C1q component; miscarriage

Mesh:

Substances:

Year:  2015        PMID: 26639463     DOI: 10.1007/s10517-015-3144-x

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  1 in total

1.  Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia.

Authors:  Douwe Jan Dijkstra; A Inkeri Lokki; Lobke Marijn Gierman; Nicole Veronique Borggreven; Carin van der Keur; Michael Eikmans; Kyra Andrea Gelderman; Hannele Laivuori; Ann-Charlotte Iversen; Marie-Louise P van der Hoorn; Leendert Adrianus Trouw
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.